Clinial implication of tThe expression of Aurora B in normal endometrium and endometrial carcinoma

Abstract

The expression of Aurora B in normal endometria and endometrial carcinomas and its relation with clinicopathologic parameters of endometrial carcinomas were investigated. Streptavidin-biotin peroxidase (SP) immunohistochemical technique was used to detect the expression of Aurora B in 10 cases of normal proliferative phase endometria, 10 cases of normal secretory phase endometria and 72 cases of endometrial carcinomas respectively. According to the 1988 International Federation of Gynecology and Obstetrics (FIGO) grade, there were 37 patients in grade 1, 23 in grade 2 and 12 in grade 3 respectively. According to the FIGO stage, there were 59 patients in stage I–II and 13 patients in stage III–IV. Aurora B was expressed in both normal proliferative phase endometria, secretory phase endometria and endometrial carcinomas, but its positive labeling index (PLI) in proliferative phase endometria was significantly higher than that in secretory phase endometria (P<0.01) and endometrial carcinomas (P<0.01). The PLI of Aurora B was lower in tumors with well differentiation (G₁), low surgical staging (I–II), and ≤1/2 myometrial invasion than that in tumors with moderate and low differentiation (G₂—G₃), higher surgical staging (III–IV), and >1/2 myometrial invasion (all P<0.01). Aurora B exerts its functions in the replication of normal endometrial glandular cells; Expression of Aurora B is significantly correlated with biologic behavior of endometrial carcinoma, indicating that Aurora B may be a promising prognostic factor in endometrial carcinoma.

Keywords

endometrium / endometrial carcinoma / Aurora B / immunohistochemistry

References

[1] AdamsR. R., CarmenaM., EarnshawW. C., et al.. Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol, 2001, 11(2): 49-54

[2] CarmenaM., EarnshawW. C.. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol, 2003, 4(11): 842-854

[3] NiggE. A.. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol, 2001, 2(1): 21-32

[4] ChieffiP., TronconeG., CaleoA., et al.. Aurora B expression in normal testis and seminomas. J Endocrinol, 2004, 181(2): 263-270

[5] LeeE. C., FrolovA., LiR., et al.. Targeting Aurora kinases for the treatment of prostate cancer. Cancer Res, 2006, 66(10): 4996-5002

[6] SorrentinoR., LibertiniS., PallanteP. L., et al.. Aurora B overexpression associated with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab, 2005, 90(2): 928-935

[7] KatayamaH., OtaT., JisakiF., et al.. Mitotic kinase expression and colorectal cancer progression. J Natl Cancer Inst, 1999, 91(13): 1160-1162

[8] QiG., OgawaI., KudoY., et al.. Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer. Virchows Arch, 2007, 450(3): 297-302

[9] CrosioC., FimiaG. M., LouryR., et al.. Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol Cell Biol, 2002, 7(1): 11-17

[10] OtaT., SutoS., KatayamaH., et al.. Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora B overexpression contributes to chromosome number instability. Cancer Res, 2002, 62(18): 5168-5177

[11] TatsukaM., KatayamaH., OtaT., et al.. Multinuclearity and increased ploidy caused by overexpression of the Aurora B and IpI1-like midbody-associated protein mitotic kinase in human cancer cells. Cancer Res, 1998, 58(21): 4811-4816

[12] ArakiK., NozakiK., UebaT., et al.. High expression of Aurora-B/Aurora and Ipll-like midbody-associated protein (AIM-1) in astrocytomas. J Neuroncol, 2004, 67(1–2): 53-64